Itratuf CP Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itratuf CP is effective against a wide range of dermatophytes, yeasts, and molds, making it suitable for managing infections such as dermatophytosis, onychomycosis, candidiasis, and systemic mycoses. The capsule formulation ensures convenient oral administration with good bioavailability when taken with food. Dosage and duration of therapy depend on the type and severity of the infection and should be determined by a healthcare professional. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored during prolonged therapy. Itratuf CP is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals and should not be co-administered with certain drugs due to potential interactions involving cytochrome P450 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and rash. Proper adherence to prescribed therapy is essential for optimal outcomes.